StockData

Mereo BioPharma vs Scienture

MREO and SCNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MREO and SCNX compare

Mereo BioPharma is the larger company, worth 1.9 times as much as Scienture ($219M against $113M).

Scienture scores higher on the StockData Score (3 against 1 for Mereo BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMREOSCNX
Size and price
Market cap$219M$113M
Share price$0.275$2.76
Change, 1 year−84.6%−82.8%
Change, 5 years−85.6%−99.8%
Beta (5Y)2.291.19
Employees398
StockData Score
Total score13 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score11
Dividend score00
Valuation
P/B9.2×1.8× (better)
FCF yield−10.1%–
Growth
Revenue growth, 5Y average–−52.1%
Profitability
Return on equity−76.6%−53.5% (better)
Return on invested capital–−47.3%
Financial health
Interest coverage−440.6×−13.1× (better)
Current ratio5.22 (better)3.04
Altman Z-score−4.680.07 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions7.1%–
Held by insiders0.18%16.6%
Short interest, % of float–0.34%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.